TRICOR (MICRONIZED) Drug Patent Profile

When do Tricor (micronized) patents expire, and when can generic versions of Tricor (micronized) launch?

Tricor (micronized) is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TRICOR (MICRONIZED) is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tricor (micronized)

A generic version of TRICOR (MICRONIZED) was approved as fenofibrate by RHODES PHARMS on May 13^th, 2005.

Summary for TRICOR (MICRONIZED)

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRICOR (MICRONIZED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-002	Feb 9, 1998		DISCN	Yes	No
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-003	Jun 30, 1999		DISCN	Yes	No
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-004	Jun 30, 1999		DISCN	Yes	No

International Patents for TRICOR (MICRONIZED)

See the table below for patents covering TRICOR (MICRONIZED) around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	517711	Procédé pour la préparation d'oximes de dérivés des acides phénoxyalcoylcarboxyliques p-carbonylés (Phenoxyacetic acid derivs)
France	2157853
Spain	2054040
Japan	S519745
Australia	614577

Last updated: February 3, 2026

What Is the Investment Outlook for TRICOR (MICRONIZED)?

TRICOR (micronized fenofibrate) is a lipid-modifying agent used primarily to reduce triglyceride levels and increase HDL cholesterol in patients with hyperlipidemia. Its popularity is driven by its established efficacy in cardiovascular risk reduction and a diverse patent and generic landscape.

What Are the Market Fundamentals for TRICOR (MICRONIZED)?

Market Size and Revenue

• The global hyperlipidemia market was valued at approximately $15 billion in 2022.
• Fenofibrate products accounted for around 20-25% of that market, roughly $3-4 billion.
• TRICOR (micronized fenofibrate) held an estimated 10-15% share of fenofibrate sales, translating to $300-600 million annually.

Key Competitors

• Losartan (ARBS), atorvastatin (statins), and other fibrates form primary competition.
• Generic fenofibrate formulations have eroded branded TRICOR's market share.
• Abbott (now part of AbbVie) markets TRICOR, with patent protection on the micronized formulation until 2018, after which generics entered.

Patent and Regulatory Status

• The original patent for TRICOR expired in 2018 in multiple jurisdictions, leading to increased generic penetration.
• Current patent protections focus on specific formulations or delivery systems; however, most market volume now resides with generics.
• Regulatory approvals in key markets (U.S., EU, Japan) maintain consistent safety and efficacy standards.

Pricing Dynamics

• Brand-name TRICOR typically sold at a premium over generics.
• Average wholesale price (AWP) for brand TRICOR ~$340 per month; generics range from $10 to $20.
• Cost erosion impacts revenue, especially in high-penetration settings.

What Are the Key Investment Drivers?

Patent Cliff and Generic Competition

• The expiration of exclusivity reduces revenue potential.
• Market share shifts from branded to generic formulations.
• Companies innovating on formulations or delivery may extend product lifecycle.

Demographic and Prescription Trends

• Growing prevalence of hyperlipidemia driven by aging populations and lifestyle factors.
• Rise in cardiovascular disease globally influences demand.

Regulatory and Market Access Factors

• Reimbursement policies influence prescribing patterns.
• Increased utilization in developing markets with expanding healthcare infrastructure.

Pipeline and Formulation Innovation

• Developing combination therapies or controlled-release formulations may provide differentiation.
• Limited pipeline activity specifically for fenofibrate; most innovation occurs in related lipid-modifying agents.

What Are the Investment Risks?

• Market saturation following patent expiry.
• Price pressures from generics.
• Competition from newer lipid agents, such as PCSK9 inhibitors or bempedoic acid.
• Regulatory changes affecting reimbursement or approval.

How Should Investors Approach TRICOR (MICRONIZED)?

• Recognize the post-patent decline phase for TRICOR; focus on legacy revenue rather than growth prospects.
• Consider companies investing in innovation or pipeline expansion in lipids and cardiovascular therapy.
• Evaluate broader hyperlipidemia market growth and demographic trends.
• Be aware of the competitive landscape that favors generic formulations over branded.

Key Takeaways

• TRICOR (micronized fenofibrate) faces substantial revenue decline due to patent expiry and generic competition.
• The hyperlipidemia market remains sizable driven by demographics and cardiovascular disease burden.
• Innovation focuses on formulation improvements or new drug classes. Opportunities for differentiation are limited for TRICOR.
• Investment should weigh declining brand revenues against the overall market growth and pipeline prospects in lipid management.

FAQs

1. Will TRICOR (MICRONIZED) recover market share post-patent?
No. Patent expirations have substantially increased generic penetration, and price competition limits potential recovery.

2. Are there new formulations of fenofibrate that could extend product life?
Some companies develop controlled-release or combination products, but none have significantly extended TRICOR’s lifecycle compared to the original.

3. How does TRICOR compare to other lipid therapies?
It is less effective in reducing LDL cholesterol compared to statins and PCSK9 inhibitors, limiting its use to specific lipid profiles.

4. What is the outlook for the hyperlipidemia market?
It remains sizable but is shifting towards newer drug classes and personalized medicine.

5. Which companies hold competitive advantages in this space?
Firms with diversified portfolios in cardiovascular drugs and pipelines in lipid-modulating agents are better positioned.

References

1. IMS Health. "Global Cardiovascular Market Analysis," 2022.
2. EvaluatePharma. "Fenofibrate Market Assessment," 2022.
3. FDA. "Drug Patent and Exclusivity Data," 2022.
4. IQVIA. "Global Prescriptions and Market Trends," 2022.
5. MarketWatch. "Hyperlipidemia Drugs Market Overview," 2023.